An experimental drug first developed for spinal cord injuries has reduced DNA damage and signs of brain inflammation in a mouse model of Alzheimer’s disease. Researchers at King’s College London say KCL-286 could offer a broader treatment strategy by targeting several disease-related processes rather than just one.
There is a head start, though. KCL-286 has already completed an early safety trial in healthy volunteers, giving researchers human data to build on. That is not evidence that it preserves memory or slows Alzheimer’s, but it could help move the drug toward further testing.
Why looking beyond amyloid matters
Alzheimer’s research has long focused on amyloid-beta and tau, proteins whose abnormal buildup is associated with the loss of brain cells. The King’s team points to DNA damage and inflammation as additional targets because both can appear early in the disease. According to the university, approved amyloid-targeting drugs have delivered limited but measurable clinical benefits.
“To develop an effective treatment for Alzheimer’s disease, we need to tackle multiple aspects of the disease,” said Natasha Hill, one of the study’s first authors. The idea is to influence several connected biological problems, not assume that targeting a single protein will address everything.
How KCL-286 aims to help cells repair DNA
KCL-286 activates retinoic acid receptor beta (RARβ), a protein involved in signaling linked to vitamin A. Activating this target can influence cellular repair pathways, which is why the researchers are investigating effects beyond a single Alzheimer’s hallmark. These findings concern KCL-286, not vitamin A supplements, which were not tested in this experiment.
The damage of interest involves both strands of DNA breaking. Neuroscience professor Jonathan Corcoran compared it to a rope cut all the way through, rather than one merely fraying at the edges. The researchers found evidence that KCL-286 helps cells address those breaks.
Earlier work on neuropathic pain had suggested the drug could promote this kind of repair. The same team had also identified molecular overlap between spinal cord injury and Alzheimer’s, giving them a reason to test whether the approach could work in a different setting.
What the mouse study actually measured
The paper reports that male mice received KCL-286 injections three times a week, from 15 to 18 months of age. There were only three animals per group, making this a small study that needs follow-up.
Brain tissue showed lower levels of a marker associated with DNA breaks and increased levels of the repair protein BRCA1. The DNA-damage marker fell but remained above levels in mice without the Alzheimer’s-related genetic changes, so this was not a complete return to normal.
Researchers also observed changes in microglia and astrocytes, cells involved in the brain’s immune and support systems. Their appearance became more consistent with reduced inflammatory activation, adding another piece of evidence for the drug’s effects.
What the human trial does and does not tell us
The separate phase 1 trial, published in 2023, enrolled 109 healthy men and assessed safety, tolerability, and how the body handled the drug. Its authors reported that KCL-286 was well tolerated under the tested conditions, with repeated dosing studied for up to seven days. It did not evaluate Alzheimer’s treatment benefits.
Researchers also found evidence that the oral drug engaged its intended receptor in white blood cells. That is useful development information, but it is not the same as showing DNA repair inside a patient’s brain or improved thinking and memory.
Professor Corcoran believes the completed safety testing could shorten the development path. Still, those results do not establish long-term safety or effectiveness in people with Alzheimer’s, a different population from the healthy volunteers who participated in the trial.
What would make this meaningful for patients?
Dr. Maria Goncalves, who managed the drug’s development, emphasized its “potential as a disease-modifying therapy.” In everyday terms, that means changing the course of Alzheimer’s rather than only easing symptoms. For families, the meaningful test would be whether people retain memory and everyday abilities, not simply whether a laboratory marker moves in the right direction.
Future studies would need to establish which patients might benefit, when treatment should begin, and whether any improvements last. Those questions remain open, and the existing safety work cannot answer them on its own.
That is the gap future research must close before these findings can support treatment decisions.
The study was published on July 8, 2026, in FEBS Open Bio.
